Drug Catalog - Product Detail
HYDROCORTISONE OINT 1% IN ABSORBASE 110GM
| NDC | Mfr | Size | Str | Form |
|---|---|---|---|---|
| 69499-0322-10 | SOLUBIOMIX LLC | 110 | 1% | NA |
Generic Name
Substance Name
Product Type
Route
Application Number
Description
DESCRIPTION Hydrocortisone 1% in Absorbase® contains 10 mg/g of micronized hydrocortisone USP in a special absorption ointment base. Absorbase® is a water-in-oil emulsion composed of cholesterolized petrolatum and purified water USP. The product will absorb water into the internal emulsion phase, yet form a hydrophobic film on the skin. Hydrocortisone USP is C21H30O5; Pregn-4-ene-3, 20-dione, 11, 17, 21-trihydroxy-, (11 beta)-, Cortisol, and has the structural formula: Action Topical corticosteroids are primarily effective as anti-inflammatory, anti-pruritic and vasoconstrictive agents. image description
How Supplied
HOW SUPPLIED: Each gram of Hydrocortisone 1% in Absorbase ® contains 10 mg of micronized Hydrocortisone USP. Supplied in a 4 oz. jar (110 g) (NDC 69499-322-10). Caution Federal law prohibits dispensing without prescription. For external use only. Pharmacist Water may bleed from this product due to the nature of the water-in-oil emulsion. This separation does not affect the stability of hydrocortisone. The Absorbase ® base should be remixed if necessary before dispensing. Store at controlled room temperature 15°-30° C (59°-86° F). Dispense in well-closed containers. STORE AT CONTROLLED ROOM TEMEPERATURE 15°-30° C (59°-86° F). Solubiomix Madisonville, LA 70447
Indications & Usage
undefined Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
Dosage and Administration
DOSAGE & ADMINISTRATION: Topical corticosteroids are generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressing should be discontinued and appropriate antimicrobial therapy instituted.